ArticleFrontiers in neurology2023
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis.
James F Howard et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
60 papers cite it
this paperpooled ittrialcites it